Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘MNK inhibition’

We’re living in uncertain and challenging times as the coronavirus impacts healthcare providers around the world and puts them in the front line of exposure.

Meetings are being cancelled or postponed as companies and institutions batten down the hatches and restrict non-essential travel. Nobody wants their employees to bring back an infection, nor does anyone want to be stranded or quarantined in a far-flung place. I expect many hospitals will also want their staff to be readily available as the number of cases escalate in many countries.

We at BSB are also carefully considering our plans and which conferences in coming months we will attend in person, and expect it will be fewer than recent years. We’ve already cancelled attendance at a couple of international meetings and are actively considering whether we will cover others remotely too.

The worlds of oncology and the coronavirus are colliding in many ways, including on the scientific level too.

It turns out that key RNA transcription factors may have a role to play as therapeutic targets for both cancer and the coronavirus.

Science is very much about making connections. In this post, we’re taking a look at one transcription factor that could be a useful target in the context of both coronaviruses and oncology.

It’s time to look through an alternative window and see an entirely different perspective…

To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

If you had told me several weeks ago that we would write over 28 posts on #AACR16 and become very interested in mouse models, then most likely I would have laughed out loud and told you not to be so ridiculous!  Here we are with the 29th one and, another, on the bromododomain landscape yet to go.  Such was the vast richness of data and concepts being discussed or presented in New Orleans for those who chose to look.

Today, I want to start the segue from AACR to ASCO coverage.

Nawlins MGRAS FIOne way to do that is through the second part of the Gems from the Post Hall series. This latest one looks at a range of intriguing new targeted therapies and novel targets that are emerging, including a pharma company with a particularly interesting early pipeline.

Several pharma companies presented interesting data on their very early compounds currently in development, plus I noticed a trend for a new class of targeted therapies to emerge, MNK inhibitors, which we will also discuss.

Companies mentioned: Bayer, Orion Pharma, Lilly, Novartis, Pfizer, Agios.

Targets mentioned: PI3K, CDK, Akt, TWEAK, FGFR, BUB1, IDH1, SMYD2, MNK

Subscribers can log-in below of you can purchase a subscription.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!